# ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

> **NCT02773849** · PHASE3 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 157 (actual)

## Conditions studied

- Superficial Bladder Cancer

## Interventions

- **BIOLOGICAL:** ADSTILADRIN

## Key facts

- **NCT ID:** NCT02773849
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-19
- **Primary completion:** 2019-05-24
- **Final completion:** 2023-05-24
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2024-07-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02773849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02773849, "ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02773849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*